Hikma US unit launches generic equivalents to Ancobon
Source - SMW
Hikma Pharmaceuticals' wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp, has launched Flucytosine Capsules USP in 250mg and 500mg strengths, the generic equivalents to Ancobon.
West-Ward's Flucytosine Capsules USP are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
Hikma said that according to IMS Health, US sales of Flucytosine Capsules USP in 250mg and 500mg strengths were approximately $47 million for the 12 months ending September 2017.
President of generics Brian Hoffmann said: 'We are very pleased to be launching this product from the West-Ward Columbus portfolio.
'We have an excellent pipeline of differentiated products that we expect will drive future growth.'
At 9:14am: (LON:HIK) Hikma Pharmaceuticals PLC share price was -4p at 1114p